Ultrasound contrast developer Acusphere has completed a $20 million private financing round. The Watertown, MA-based company received over $19 million in funding, with additional funding commitments scheduled to close in June.
Acusphere said it would use the proceeds to fund continued advancement of its products, particularly its AI-700 ultrasound contrast agent, which recently entered phase III clinical trials. AI-700 is designed for use in detecting coronary artery disease in patients with ischemic heart disease.
By AuntMinnie.com staff writersApril 21, 2003
Related Reading
Acusphere launches phase III trials, February 26, 2003
Acusphere raises $15 million, July 24, 2002
Acusphere US contrast agent research presented at ASE, July 19, 2001
Copyright © 2003 AuntMinnie.com